4//SEC Filing
Pfizer Ventures (US) LLC 4
Accession 0000078003-19-000071
CIK 0001773427other
Filed
Sep 18, 8:00 PM ET
Accepted
Sep 19, 4:19 PM ET
Size
19.3 KB
Accession
0000078003-19-000071
Insider Transaction Report
Form 4
PFIZER INC
10% Owner
Transactions
- Conversion
Junior Series A Convertible Preferred Stock
2019-09-17−6,437,500→ 0 total→ Common Stock (978,194 underlying) - Conversion
Common Stock
2019-09-17+526,602→ 4,543,847 total - Conversion
Series A Convertible Preferred Stock
2019-09-17−20,000,000→ 0 total→ Common Stock (3,039,051 underlying) - Conversion
Common Stock
2019-09-17+978,194→ 978,194 total - Conversion
Common Stock
2019-09-17+3,039,051→ 4,017,245 total - Purchase
Common Stock
2019-09-17$18.00/sh+50,000$900,000→ 4,593,847 total - Conversion
Series B Convertible Preferred Stock
2019-09-17−3,465,571→ 0 total→ Common Stock (526,602 underlying)
Pfizer Ventures (US) LLC
10% Owner
Transactions
- Conversion
Common Stock
2019-09-17+3,039,051→ 4,017,245 total - Conversion
Common Stock
2019-09-17+526,602→ 4,543,847 total - Conversion
Common Stock
2019-09-17+978,194→ 978,194 total - Purchase
Common Stock
2019-09-17$18.00/sh+50,000$900,000→ 4,593,847 total - Conversion
Series A Convertible Preferred Stock
2019-09-17−20,000,000→ 0 total→ Common Stock (3,039,051 underlying) - Conversion
Series B Convertible Preferred Stock
2019-09-17−3,465,571→ 0 total→ Common Stock (526,602 underlying) - Conversion
Junior Series A Convertible Preferred Stock
2019-09-17−6,437,500→ 0 total→ Common Stock (978,194 underlying)
Footnotes (5)
- [F1]Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. ("Pfizer").
- [F2]Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer.
- [F3]Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer ("PVUS").
- [F4]PVUS purchased such additional shares of Common Stock in the Issuer's initial public offering at the initial public offering price of $18.00 per share.
- [F5]Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein.
Documents
Issuer
SpringWorks Therapeutics, Inc.
CIK 0001773427
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001776087
Filing Metadata
- Form type
- 4
- Filed
- Sep 18, 8:00 PM ET
- Accepted
- Sep 19, 4:19 PM ET
- Size
- 19.3 KB